MDT

86.26

-0.61%↓

A

118.39

-1.65%↓

VEEV

167.79

+0.74%↑

HQY

85.02

+3.41%↑

NEOG

9.24

-2.22%↓

MDT

86.26

-0.61%↓

A

118.39

-1.65%↓

VEEV

167.79

+0.74%↑

HQY

85.02

+3.41%↑

NEOG

9.24

-2.22%↓

MDT

86.26

-0.61%↓

A

118.39

-1.65%↓

VEEV

167.79

+0.74%↑

HQY

85.02

+3.41%↑

NEOG

9.24

-2.22%↓

MDT

86.26

-0.61%↓

A

118.39

-1.65%↓

VEEV

167.79

+0.74%↑

HQY

85.02

+3.41%↑

NEOG

9.24

-2.22%↓

MDT

86.26

-0.61%↓

A

118.39

-1.65%↓

VEEV

167.79

+0.74%↑

HQY

85.02

+3.41%↑

NEOG

9.24

-2.22%↓

Search

Charles River Laboratories International Inc

Aperta

SettoreSettore sanitario

179.88 -1.33

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

178.12

Massimo

184.23

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+9.27% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

859M

8.8B

Apertura precedente

181.21

Chiusura precedente

179.88

Notizie sul Sentiment di mercato

By Acuity

48%

52%

163 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 apr 2026, 23:14 UTC

Utili

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15 apr 2026, 23:14 UTC

Utili

Battery Maker CATL First Quarter Net Rose On Strong Demand

15 apr 2026, 17:13 UTC

I principali Market Mover

Tesla Shares Rise on Completion of AI5 Chip Design Process

15 apr 2026, 23:39 UTC

Discorsi di Mercato

Nikkei May Rise After Gains on Wall Street -- Market Talk

15 apr 2026, 23:35 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15 apr 2026, 22:41 UTC

Utili

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15 apr 2026, 22:38 UTC

Utili

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15 apr 2026, 22:15 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

15 apr 2026, 22:15 UTC

Discorsi di Mercato

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15 apr 2026, 22:14 UTC

Utili

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15 apr 2026, 22:12 UTC

Utili

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15 apr 2026, 22:11 UTC

Utili

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15 apr 2026, 22:11 UTC

Utili

Lens Technology Swings to Loss in 1Q>300433.SZ

15 apr 2026, 22:07 UTC

Utili

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15 apr 2026, 21:34 UTC

Acquisizioni, Fusioni, Takeovers

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15 apr 2026, 21:29 UTC

Azioni calde

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15 apr 2026, 20:50 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

15 apr 2026, 20:30 UTC

Utili

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15 apr 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

15 apr 2026, 20:06 UTC

Discorsi di Mercato

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15 apr 2026, 19:46 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15 apr 2026, 19:25 UTC

Discorsi di Mercato

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15 apr 2026, 19:00 UTC

Discorsi di Mercato

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15 apr 2026, 18:58 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15 apr 2026, 18:11 UTC

Acquisizioni, Fusioni, Takeovers

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15 apr 2026, 17:45 UTC

Acquisizioni, Fusioni, Takeovers

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15 apr 2026, 16:58 UTC

Utili

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15 apr 2026, 16:52 UTC

Utili

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15 apr 2026, 16:46 UTC

Discorsi di Mercato
Principali Notizie su Eventi

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15 apr 2026, 16:37 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

9.27% in crescita

Previsioni per 12 mesi

Media 197.3 USD  9.27%

Alto 235 USD

Basso 160 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

7

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

163 / 348 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat